Featured Clinical Trial:
Multiple myeloma (product/compound: lenalidomide, dexamethasone, elotuzumab)
ClinicAid Locations: Southern California – Fountain Valley, Corona, Riverside
Status:
Open for enrollment (accepting patients). Please contact us and mention Trial ID NCT01239797.
Condition: Multiple Myeloma
Product Name/Compound: Lenalidomide, Dexamethasone, Dexamethasone (Oral), Dexamethasone (IV), Elotuzumab
Full Study Title: Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma
Study Summary: The purpose of the study is to determine whether the addition of elotuzumab to lenalidomide/low-dose dexamethasone will increase the progression free survival (PFS).
Eligible Participants:
Inclusion (Eligible):
- Men and women >= 18 years of age
- Documented progression from most recent line of therapy
- 1 - 3 prior lines of therapy
- Measurable disease
- Life expectancy >=3 months
- Prior treatment with lenalidomide permitted if:
- Best response achieved was >= Partial Response (PR)
- Patient was not refractory
- Patient did not discontinue due to a Grade >= 3 related adverse event
Exclusion (Not Eligible):
- Subjects with non-secretory or oligo-secretory or free light-chain only myeloma
- Active plasma cell leukemia
- Positive for Hepatitis B, C or Human Immunodeficiency Virus (HIV)
Study Phase: Phase III (What are Phases?)
To receive information and updates for this trial:
Please contact us and mention the Trial ID below.
Trial ID (ClinicalTrials.gov): NCT01239797
<< Back to all ClinicAid clinical trials
